VitalConnect Inc has closed its final Series C round, acquiring $38 million

By Catherine Sturman
Wearable biosensor technology company VitalConnect has acquired $38 million in its Series C funding round. Led by MVM and Baxter Ventures. VitalConnect...

Wearable biosensor technology company VitalConnect has acquired $38 million in its Series C funding round. Led by MVM and Baxter Ventures. VitalConnect will launch its VitalConnect Platform and VitalPatch wearable biosensor in hospitals and outpatient settings across the US.

The company’s VitalPatch encompasses a number of sophisticated biosensors which are able to communicate health information in real-time to health professionals surrounding a user’s ongoing patient care, providing increased freedom and flexibility. The technology will be able to sense skin temperature via a thermistor, heart rate variability, fall protection, respiratory rate and much more.

The patch has a battery life of four days, and has a software platform embedded which is linked to a number of select hospitals. It is currently the smallest and lightest Class 2 medical device approved by the US Food and Drug Administration on the market.  

Related stories

"We envision a hospital of the future where inpatient and outpatient care needs integrate more seamlessly to enable a patient-centric model of care that is truly preventative and real-time,” commented Nersi Nazari, CEO and founder, VitalConnect.

“Our close of $38 million in total financing this year will help drive our continued product development and rollout."

Supporting the technology, the VitalConnect platform will provide predictive analytics to enable health professionals to respond immediately, and will be able to respond days in advance if patients’ symptoms flag any sign of potential abnormalities through biometric trends.

Providing a continuous flow of data, VitalConnect will therefore provide a one-stop solution in four principal market segments: hospital monitoring, post-discharge monitoring, remote patient monitoring and clinical trials.

Share

Featured Articles

Workplace Health Provision Easing Burden on Public Health

A Q&A with David Joerring, Founder & CEO of HealthKey, which connects health insurers and employers with digital health providers through API integrations

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Medical Devices & Pharma

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma